缺氧诱导因子脯氨酰羟化酶抑制剂对血管钙化的作用

Effect of hypoxia inducible factor-prolyl hydroxylase inhibitor on vascular calcification

摘要:

肾性贫血是慢性肾脏病（CKD）常见的并发症，近年来，低氧诱导因子脯氨酰羟化酶抑制剂（HIF-PHIs）已被开发作为肾性贫血的新型口服治疗药物。血管钙化是CKD患者心血管事件发病率和病死率增加的主要危险因素，研究表明HIF-PHIs有促进血管钙化的可能，因此充分了解HIF-PHIs潜在的危害性并加以重视非常重要。该文就HIF-PHIs在血管钙化中的作用进行综述，为临床治疗提供思路。

Abstract:

Renal anemia is a common complication of chronic kidney disease (CKD). In recent years, hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHIs) has been developed and become a new oral drug for the treatment of renal anemia. Vascular calcification is the main risk factor for the increase of incidence rate and mortality of CKD patients. The study shows that HIF-PHIs has the potential to promote vascular calcification. Therefore, it is important to fully understand the potential hazards of HIF-PHIs and overcome them. This paper discusses the role of hif-phis in vascular calcification, in order to summarize its research progress and provide ideas for clinical treatment.